Ulrika Rosenström
Senior Lecturer/Associate Professor at Department of Medicinal Chemistry; Preparative Medicinal Chemistry
- Telephone:
- +46 18 471 42 97
- E-mail:
- ulrika.rosenstrom@ilk.uu.se
- Visiting address:
- Uppsala Biomedicinska Centrum, BMC, Husarg. 3
- Postal address:
- Box 574
751 23 UPPSALA
More information is available to staff who log in.
Short presentation
Biography
Ulrika received a Master of Science in Chemistry from Uppsala University in 1996 and was appointed as a scientist at Pharmacia and Upjohn. In 1999 she started her dissertation work in Medicinal Chemistry under Prof Anders Hallberg and in 2004 she became Doctor of Philosophy (Faculty of Pharmacy). In 2005 she was appointed a position as researcher and lecturer at the Division of Organic Pharmaceutical Chemistry and 2007 she became Chemistry director and scientist at Cardoz AB, a small biotech company in preclinical and clinical phase. In 2011 she returned to Uppsala University as a researcher and lecturer. Her main research interests are: synthesis of peptides and pseudopeptides as novel PET-radiotracers, and design and synthesis of both drug-like and peptidomimetic enzyme inhibitors.
Publications
Recent publications
- Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m (2024)
- Inhibition of Insulin-Regulated Aminopeptidase by Imidazo[1,5-α]pyridines; Synthesis and Evaluation (2024)
- Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer (2024)
- Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker (2024)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
All publications
Articles
- Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m (2024)
- Inhibition of Insulin-Regulated Aminopeptidase by Imidazo[1,5-α]pyridines; Synthesis and Evaluation (2024)
- Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer (2024)
- Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker (2024)
- 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry (2023)
- Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA) (2023)
- Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer (2023)
- Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands (2022)
- Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1 (2021)
- Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis (2021)
- Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors (2020)
- Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model (2020)
- Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer (2019)
- Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26 (2019)
- Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 (2019)
- Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer (2019)
- Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart (2019)
- GRPR-targeted radiotherapy using the Lu-177-labeled GRPR-antagonist DOTAGA-PEG(2)-RM26 (2018)
- Selection of optimal macrocyclic chelator for high contrast PET imaging of gastrin releasing peptide receptor using cobalt-labeled bombesin antagonist RM26 (2018)
- Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [Ga-68]Ga-DO3A-VS-Cys(40)- Exendin-4/PET (2018)
- Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4 (2017)
- High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26 (2017)
- GRPR-Targeted Radiotherapy (2017)
- Fully automated GMP production of [Ga-68]Ga-DO3A-VS-Cys(40)-Exendin-4 for clinical use (2017)
- Binding to and Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Macrocyclic Disulfides Enhances Spine Density (2016)
- Aryl Sulfonamide Inhibitors of Insulin-Regulated Aminopeptidase Enhance Spine Density in Primary Hippocampal Neuron Cultures (2016)
- Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening (2016)
- Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. (2016)
- Feasibility of Multiple Examinations Using Ga-68-Labelled Collagelin Analogues (2016)
- Ga-68/PET imaging and quantification of fibrosis using peptide-based tracers (2016)
- Development of radiocobalt-labeled GRPR antagonist NOTA-PEG2-RM26. (2015)
- Influence of chelators on targeting properties of In-111 and Ga-68 labeled GRPR antagonist (2015)
- The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26 (2015)
- Rat organ distribution of [Lu-177]-DO3A-VS-Cys(40)-Exendin-4 for the estimation of human dosimetry (2015)
- Extrapolated dosimetry of two novel Ga-68-labelled imaging agents for fibrosis (2015)
- Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides (2014)
- Nonresonant microwave heated continuous flow synthesis in medicinal chemistry (2014)
- Microwave Heated Flow Synthesis of Spiro-oxindole Dihydroquinazolinone Based IRAP Inhibitors (2014)
- Influence of chelators on biodistribution and targeting properties of GRPR antagonist (2014)
- The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a Ga-68-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin (2014)
- Synthesis and preclinical evaluation of Ga-68-labeled collagelin analogs for imaging and quantification of fibrosis (2014)
- Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic – targeting Mycobacterium tuberculosis ribonucleotide reductase (2013)
- Synthesis and preclinical evaluation of Ga-68-labelled collagelin analogues for imaging and quantification of fibrosis (2013)
- Selective angiotensin II AT2 receptor agonists (2008)
- Short pseudopeptides containing turn scaffolds with high AT(2) receptor affinity (2006)
- Design, synthesis, and incorporation of a beta-turn mimetic in angiotensin II forming novel pseudopeptides with affinity for AT(1) and AT(2) receptors (2006)
- New selective AT2 receptor ligands encompassing a γ-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists (2005)
- Synthesis and AT2 receptor-binding properties of angiotensin II analogues (2004)
- A Selective AT2 Receptor Ligand with a γ-Turn-Like Mimetic replacing the Amino Acid Residues 4-5 of Angiotensin II (2004)
- Synthesis and Preclinical Evaluation of GRPR Antagonist [18F]-MeTz-PEG2-RM26 for Position Emission Tomography